TNF and rheumatoid arthritis: Neutralization of TNFα using either anti-TNFα antibodies or the soluble decoy receptor for TNFα has been instrumental in reducing the severity of arthritis, and a variety of biologics (e.g., infliximab, etanercept, etc.) based on this concept are currently being used in the clinic for the treatment of RA (Table 1).